Versant Capital Management’s ADMA Biologics ADMA Stock Holding History

Versant Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$937	Sell	112 -766	-87%	-$6.98K	﹤0.01%	2647
2026 Q1	$7.91K	Sell	878 -971	-53%	-$15.3K	﹤0.01%	2231
2025 Q4	$33.7K	Buy	1,849 +1,277	+223%	+$21.5K	﹤0.01%	1317
2025 Q3	$8.39K	Sell	572 -123	-18%	-$2.11K	﹤0.01%	2014
2025 Q2	$12.7K	Sell	695 -11	-2%	-$224	﹤0.01%	1781
2025 Q1	$14K	Buy	+706	New	+$12.2K	﹤0.01%	1535

Other funds holding ADMA

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

MCM

Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return

PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Versant Capital Management's ADMA Position: Q2 2026 in Review

Versant Capital Management reduced its ADMA Biologics (ADMA) stake by 87% in Q2 2026, selling an estimated $6.98K and leaving 112 shares worth $937. The position accounts for ﹤0.01% of the portfolio, ranked #2647.

Versant Capital Management first reported a position in ADMA in Q1 2025 and has held it in 6 quarters since. The position peaked at $33.7K in Q4 2025. 54 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Versant Capital Management held 112 shares of ADMA Biologics worth $937 as of Q2 2026.
Versant Capital Management sold 766 ADMA Biologics shares in Q2 2026, an estimated $6.98K.
ADMA Biologics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2647 holding.
Versant Capital Management first reported a position in ADMA Biologics in Q1 2025 and has held it in 6 quarters since.
Versant Capital Management's ADMA Biologics position peaked at $33.7K in Q4 2025.
54 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.